Lipoxen Simultaneously Acquires Symbiotec
Russia's SynBio Purchases Majority Stake in UK's Lipoxen
By Nuala Moran
Monday, August 8, 2011
LONDON Drug delivery specialist Lipoxen plc is selling a majority, £12.8 million (US$20.9 million), stake in the company to SynBio LLC, a firm that is majority-owned by the government of Russia, as one of a series of moves to transform itself into a mainstream drug developer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.